Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019

被引:148
作者
Golabi, Pegah [1 ]
Paik, James M. [1 ,2 ]
AlQahtani, Saleh [3 ,4 ]
Younossi, Youssef [4 ]
Tuncer, Gabriela [1 ]
Younossi, Zobair M. [1 ,3 ,5 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] Ctr Liver Dis, Dept Med, Inova Fairfax Med Campus, Falls Church, VA USA
[3] Johns Hopkins Med Ctr, Baltimore, MD USA
[4] Ctr Outcomes Res Liver Dis, Washington, DC USA
[5] Inova Hlth Syst, Inova Med, Falls Church, VA USA
关键词
liver cancer; cirrhosis; trends; DALY; Asia; NAFLD; NASH; metabolic syndrome; STEATOHEPATITIS; FIBROSIS; OBESITY; NAFLD; TRANSPLANTATION; PROGRESSION; PREVALENCE;
D O I
10.1016/j.jhep.2021.05.022
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aim: Non-alcoholic fatty liver disease (NAFLD) has become a major cause of chronic liver disease (CLD) worldwide. Our aim was to assess the burden of liver complications (LC, cirrhosis and liver cancer) related to NAFLD (LC-NAFLD) between 2009-2019 in Asia and the Middle East and North Africa (MENA) region. Methods: We used Global Burden of Disease data to assess incidence, mortality, and disability-adjusted life years (DALYs) for LC-NAFLD from Asia and the MENA region. Annual % change (APC) in rates were computed using a joinpoint regression model. Associations of LC-NAFLD with low physical activity, diet and metabolic risks were determined by partial Spearman correlation coefficients (rho). Results: Globally in 2019, there were 170,000 incident cases of LC-NAFLD, accounting for 6.6% of LC incident cases from all CLDs. There were 168,969 deaths related to LC-NAFLD, accounting for 8.6% of LC deaths from all CLDs. Asia accounted for 48.3% of the global incidence of LC-NAFLD and for 46.2% of deaths attributable to LC-NAFLD, while MENA accounted for 8.9% and 8.6%, respectively. There were 2.08 million DALYs in Asia and 340,000 DALYs in MENA. From 2009 to 2019, regions in Asia and MENA experienced a rise in DALYs attributable to LC-NAFLD (compared to LC from other CLDs), ranging from South Asia (APC = +2.12% vs. 0.94%) to high-income Asia Pacific (APC = -0.07%, p = 0.646 vs. 0.97%). In Asia, NAFLD-related DALYs were significantly correlated with dietary risks (95% CI 0.280-0.763, p = 0.004), metabolic risks (0.341-0.790, p <0.001) and tobacco use (0.134-0.691, p = 0.007). In MENA, low physical activity (0.557-0.918, p <0.001), metabolic risks (0.432-0.888, p = 0.001), and dietary risks (0.315-0.855, p = 0.001) correlated with DALYs. Conclusions: NAFLD is posing a substantial burden in Asia and MENA. About half of the global burden of LC-NAFLD is accounted for by these regions. Lay summary: Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the most common causes of chronic liver disease worldwide. We used Global Burden of Disease data to assess the incidence, mortality, and disability-adjusted life years attributable to NAFLD-related liver complications in Asia, the Middle East and North Africa. NAFLD is poised to contribute to a substantial liver disease burden in these regions. Regional and global policies are needed to address the increasing burden of complications of NAFLD. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:795 / 809
页数:16
相关论文
共 46 条
  • [1] Ahmed MH, 2017, GASTROENTEROL RES, V10, P271, DOI 10.14740/gr913w
  • [2] The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015
    Akinyemiju, Tomi
    Abera, Semaw
    Ahmed, Muktar
    Alam, Noore
    Alemayohu, Mulubirhan Assefa
    Allen, Christine
    Al-Raddadi, Rajaa
    Alvis-Guzman, Nelson
    Amoako, Yaw
    Artaman, Al
    Ayele, Tadesse Awoke
    Barac, Aleksandra
    Bensenor, Isabela
    Berhane, Adugnaw
    Bhutta, Zulfiqar
    Castillo-Rivas, Jacqueline
    Chitheer, Abdulaal
    Choi, Jee-Young
    Cowie, Benjamin
    Dandona, Lalit
    Dandona, Rakhi
    Dey, Subhojit
    Dicker, Daniel
    Phuc, Huyen
    Ekwueme, Donatus U.
    Zaki, Maysaa El Sayed
    Fischer, Florian
    Furst, Thomas
    Hancock, Jamie
    Hay, Simon I.
    Hotez, Peter
    Jee, Sun Ha
    Kasaeian, Amir
    Khader, Yousef
    Khang, Young-Ho
    Kumar, G. Anil
    Kutz, Michael
    Larson, Heidi
    Lopez, Alan
    Lunevicius, Raimundas
    Malekzadeh, Reza
    McAlinden, Colm
    Meier, Toni
    Mendoza, Walter
    Mokdad, Ali
    Moradi-Lakeh, Maziar
    Nagel, Gabriele
    Nguyen, Quyen
    Nguyen, Grant
    Ogbo, Felix
    [J]. JAMA ONCOLOGY, 2017, 3 (12) : 1683 - 1691
  • [3] Liver transplantation for nonalcoholic steatohepatitis in young patients
    Alkhouri, Naim
    Hanouneh, Ibrahim A.
    Zein, Nizar N.
    Lopez, Rocio
    Kelly, Dympna
    Eghtesad, Bijan
    Fung, John J.
    [J]. TRANSPLANT INTERNATIONAL, 2016, 29 (04) : 418 - 424
  • [4] Alswat K, 2018, SAUDI J GASTROENTERO, V24, P211, DOI [10.4103/sjg.SJG_122_18, 10.4103/sjg.sjg_122_18]
  • [5] [Anonymous], 2020, GLOBAL BURDEN DIS ST
  • [6] [Anonymous], 2015, An Integrative Metaregression Framework for Descriptive Epidemiology
  • [7] Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
    Anstee, Quentin M.
    Targher, Giovanni
    Day, Christopher P.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) : 330 - 344
  • [8] Anushiravani Amir, 2019, Middle East J Dig Dis, V11, P189, DOI [10.15171/middle%20east%20j%20di.v11i4.2171, 10.15171/mejdd.2019.147]
  • [9] Burden of liver diseases in the world
    Asrani, Sumeet K.
    Devarbhavi, Harshad
    Eaton, John
    Kamath, Patrick S.
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : 151 - 171
  • [10] Metabolic health in the Middle East and north Africa
    Azizi, Fereidoun
    Hadaegh, Farzad
    Hosseinpanah, Farhad
    Mirmiran, Parvin
    Amovzegar, Atieh
    Abdi, Hengameh
    Asghari, Golaleh
    Parizadeh, Donna
    Montazeri, Seyed Ali
    Lotfaliany, Mojtaba
    Takyar, Farzin
    Khali, Davood
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11) : 866 - 879